Polymeric drug delivery system for treating surgical complications

A polymer and drug technology, applied in the field of polylactic acid, can solve the problems of sternal wound infection and the incidence of mediastinitis are not very effective

Inactive Publication Date: 2016-03-23
TYRX
View PDF22 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] Although prophylactic antibiotics are the standard of care before most surgical procedures, IV antibiotics alone are not very effective in reducing the incidence of sternal wound infection and mediastinitis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymeric drug delivery system for treating surgical complications
  • Polymeric drug delivery system for treating surgical complications
  • Polymeric drug delivery system for treating surgical complications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0196] Embodiment 1: the preparation of polymer-drug powder

[0197] Tyrosine polyesteramide (P22-27.5) powders containing rifampicin (10%) and minocycline (10%) drugs were prepared by grinding polymer films. Polymer films containing rifampicin and minocycline were prepared by solvent casting. Briefly, 8 g of tyrosine polyester amide P22-27.5 were dissolved in 36 ml of THF. In separate vials, 1 g of rifampicin and 1 g of minocycline were dissolved in 4 ml of methanol. The two solutions were mixed and poured into TEFLON pans (10 cm diameter x 1.9 cm depth). The solution was left in a fume hood at room temperature for 16-18 hours to evaporate the solvent. Place the dish in a 50°C oven under vacuum for 24 hours. The formulation foamed and formed a film. The film was crushed into a powder using a small mixer. As a result, 8.7 g of tyrosine polyester amide polymer powders containing 10% each of rifampicin and minocycline in the MW range of 6 kDa to 70000 kDa were prepared by ...

Embodiment 2

[0198] Example 2: Preparation of PEG-polymer formulations

[0199] Various formulations were prepared in which P22-27.5-drug powder was combined with various ratios of PEG (MW400) to obtain various polymer-drug powder combinations. Table 2 below shows the different combinations.

[0200] Table 2: P22-27.5-rifampicin-minocycline formulations with PEG400

[0201] #

Embodiment 3

[0202] Embodiment 3: Viscosity determination

[0203] The viscosity of the oily (lubricating oil) formulations was measured on a Brookfield viscometer (Model DVII+Pro, Brookfield Engineering Lab Inc., Middleboro, MA) equipped with a thermometer and 4 different spindles. Formulation #5 mentioned in Table 2 was taken into a 20ml scintillation vial and the viscosity was measured using spindle #63 at a shear rate of 10 rpm under ambient conditions. The viscosity of the formulation is 2230-2260 cp (centipoise).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
number average molecular weightaaaaaaaaaa
Login to view more

Abstract

A composition comprising a polymer and at least one active agent, wherein the composition is formulated for topical application and shows thermally reversible behavior or inverse thermally reversible behavior. The active agent of the composition is an antimicrobial, an anti-inflammatory agent, anesthetic or mixtures thereof. A method of preparing the composition is also provided.

Description

Background technique [0001] Surgery opens the door to life-saving procedures; unfortunately, it is the physical exposure that makes it susceptible to postoperative infection. Pacemakers are the best example. The number of patients receiving pacemaker implantation is steadily increasing, with over 1 million patients implanted with the device in 2009. However, due to this rise in surgical procedures, the number of surgical site infections (SSIs) has also increased. Infection occurs in 3% of patients receiving a cardiac implantable electronic device (CIED), with an average treatment cost of $146,000. Mortality rates associated with CIED range from 27% to 35%. Many patients will receive a pacemaker without complications, but for patients who suffer from infection, the costs are high both physically and financially. [0002] In addition to infection control after surgery, pain must also be closely monitored; the Department of Veterans Affairs refers to pain as the "fifth" vital...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K45/00A61K45/06A61K47/34A61K31/65A61P29/00A61P31/04A61K31/496
CPCA61K9/0014A61K9/146A61K31/496A61K31/65A61K45/00A61K45/06A61K47/10A61K47/34A61K2300/00A61P29/00A61P31/04A61K47/32
Inventor 拉曼·巴乌莱卡尔威廉·麦克詹姆斯法蒂玛·布厄维奇萨蒂施·普尔阿普拉
Owner TYRX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap